NBIX 8-K 2026-09-28
NEUROCRINE BIOSCIENCES INC (NBIX) 8-K dated 2026-09-28 — accession 0000914475-26-000045.
NEUROCRINE BIOSCIENCES INC (NBIX) is a drug manufacturers - specialty & generic company listed on US.
NEUROCRINE BIOSCIENCES INC filed a 8-K on 2026-09-28. Accession 0000914475-26-000045.
This 8-K covers: Director/officer change (Item 5.02). SEC EDGAR holds the official filing and its exhibits.
Latest reported NBIX revenue for 2025-12-31 was $2.86B. Net income was $478.6M. Revenue was up 21.4% from 2024-12-31 to 2025-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 24.6.
Not investment advice. The NBIX SEC hub lists recent forms. The stock page is the research view.